Septerna, INC Form 4 insider transactions

Septerna, Inc. Director Keith Michael Gottesdiener was granted 33,246 stock options with an exercise price of $16.75, vesting monthly over three years.

Septerna's SVP of Biological Sciences, Uwe Klein, exercised stock options to acquire 23,008 shares of common stock at prices ranging from $2.76 to $6.81, effective August 18, 2025.

Septerna's Chief People Officer, Samira Shaikhly, was granted 30,000 stock options with a $11.7 exercise price, vesting monthly over four years.

Septerna, Inc.'s President and COO, Elizabeth Bhatt, was granted 95,000 stock options with an exercise price of $11.7, vesting monthly over four years.

Septerna's Chief Medical Officer, Jae B. Kim, was granted 55,000 stock options with an exercise price of $11.70, vesting over approximately four years.

Septerna Inc.'s Chief Financial Officer, Gil M Labrucherie, acquired 37,500 stock options with a vesting schedule tied to continued service.

Septerna, Inc. CEO Jeffrey Finer was granted 210,000 stock options with an exercise price of $11.70, vesting over four years.

Septerna Inc.'s SVP of Drug Discovery, Daniel D. Long, was granted 30,000 stock options with a future vesting schedule.

Septerna, Inc. SVP of Biological Sciences, Uwe Klein, was granted 30,000 stock options with an exercise price of $11.70, vesting monthly over four years.

RA Capital Management, a significant shareholder and director of Septerna, Inc., has disclosed the grant of 16,623 stock options to director Jake Simson, exercisable at $10.24 per share.

Septerna, Inc. Director Shalini Sharp has been granted 16,623 stock options with an exercise price of $10.24, aligning her interests with long-term shareholder value.

Septerna, Inc. Director and 10% Owner Jeffrey K. Tong was granted 16,623 stock options with an exercise price of $10.24 per share, vesting upon continued service.

Septerna, Inc. Director Bernard Coulie was granted 16,623 stock options with an exercise price of $10.24, vesting by June 2026 or the next annual meeting, as reported in a recent SEC Form 4 filing.

Septerna, Inc. Director Jake Simson was granted 16,623 stock options with an exercise price of $10.24, vesting upon the earlier of June 17, 2026, or the company's next annual meeting.

Septerna, Inc. Director Abraham Bassan was granted 16,623 stock options with an exercise price of $10.24, aligning his interests with shareholder value.

Septerna, Inc. Director Alan Ezekowitz was granted 16,623 stock options with an exercise price of $10.24, vesting upon the earlier of June 17, 2026, or the company's next annual meeting of stockholders.

Septerna's CEO, Jeffrey Finer, exercised stock options on April 2nd and 3rd, 2025, increasing his direct ownership of common stock.

Director Alan Ezekowitz reports purchasing 13,319 shares of Septerna, Inc. common stock at an average price of $6.9277.

Director Alan Ezekowitz reported purchasing Septerna, Inc. (SEPN) common stock in multiple transactions between March 4th and March 6th, 2025, increasing his holdings.

Septerna's CEO, Jeffrey Finer, has recently acquired additional shares of the company's common stock through a series of transactions.

Gil M Labrucherie, CFO of Septerna, Inc., reports purchasing shares of common stock in two transactions.

Third Rock Ventures VI, L.P. reports the purchase of additional Septerna, Inc. common stock at an average price of $5.999 per share.

Third Rock Ventures, a significant shareholder in Septerna, Inc., has increased its holdings through a series of open market purchases, as detailed in a recent SEC Form 4 filing.

Gil M. Labrucherie, CFO of Septerna, Inc., recently purchased shares of the company's common stock through a trust, increasing his indirect beneficial ownership.

Gil M Labrucherie, CFO of Septerna Inc., reports the acquisition of stock options.

RA Capital Management and related entities report changes in beneficial ownership of Septerna, Inc. common stock following the conversion of preferred stock in connection with the company's IPO.

Third Rock Ventures files Form 4, detailing conversion of preferred stock to common stock and transactions following Septerna, Inc.'s initial public offering.